이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) in Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy

2026년 11월 15일 업데이트: Huang Jinhua, Sun Yat-sen University

Chemotherapy-Minimized, Blank Microsphere-Based Transarterial Chemoembolization (BMS-TACE) in Patients With BCLC Stage B/C Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy: A Single-Center, Single-Arm, Phase 2 Trial

FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) is widely used for advanced hepatocellular carcinoma (HCC) in China, yet many patients show primary resistance or progress after an initial response, and no prospective trial has defined the optimal salvage strategy. This single-center, single-arm, phase 2 trial evaluates the efficacy and safety of chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE) in patients with BCLC stage B/C HCC resistant to FOLFOX-HAIC. In BMS-TACE, blank microspheres are the principal embolic agent and chemotherapy is used only as an adjunct at a minimal dose (low-dose pirarubicin in a small volume of lipiodol), in order to limit chemotherapy-related liver injury and systemic toxicity and to allow repeated embolization in patients with limited hepatic reserve. Forty-three participants will be enrolled using a Simon two-stage design. The primary endpoint is objective response rate by investigator assessment using mRECIST.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

43

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Guangdong
      • Guangzhou, Guangdong, 중국, 510060
        • 모병
        • Sun Yat-sen University Cancer Center
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Written informed consent
  • Age 18-75 years, any sex
  • Hepatocellular carcinoma confirmed by histology or cytology, or diagnosed clinically according to AASLD criteria
  • BCLC stage C, or BCLC stage B beyond the up-to-seven criteria
  • At least 4 prior cycles of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC), with stable disease or progressive disease per RECIST 1.1 on contrast-enhanced CT or MRI performed 1-3 months after the last HAIC cycle
  • Portal vein, hepatic vein or inferior vena cava tumor thrombus and distant metastasis are permitted
  • Not a candidate for surgical resection as judged by the treating physician
  • Child-Pugh score ≤ 7
  • ECOG performance status 0-1
  • Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10^9/L; hemoglobin ≥ 70 g/L; platelet count ≥ 50 × 10^9/L; white blood cell count ≥ 3.0 × 10^9/L
  • Adequate hepatic function: serum albumin ≥ 28 g/L; total bilirubin ≤ 3.0 mg/dL; AST and ALT ≤ 5 × upper limit of normal (ULN)
  • Adequate renal function: serum creatinine ≤ 1.5 × ULN
  • Adequate coagulation (not on anticoagulants): INR ≤ 2.3
  • Active hepatitis B virus infection: on antiviral therapy per local standard of care and willing to continue during the study
  • Hepatitis C virus antibody positive: on antiviral therapy per local standard of care and willing to continue during the study

Exclusion Criteria:

  • History of hypersensitivity or intolerance to any agent used in the study
  • Uncontrolled clinically significant ascites (not controlled by diuretics or paracentesis)
  • History of hepatic encephalopathy
  • Clinically significant gastrointestinal bleeding within 30 days before enrollment, or variceal bleeding within the past 3 months
  • Uncorrectable coagulopathy or marked hematological abnormality with evident bleeding tendency
  • Significant cardiovascular disease: congestive heart failure of NYHA class II or higher, unstable angina, myocardial infarction, or arrhythmia requiring medical treatment
  • History of congenital long QT syndrome, or corrected QT interval > 480 ms (Fridericia)
  • Left ventricular ejection fraction < 45%
  • Inadequately controlled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg)
  • Urine protein ≥ 1 g/24 h (24-hour urine collection required if dipstick ≥ 1+)
  • Prior organ transplantation
  • Gastrointestinal malabsorption or any other condition that in the investigator's opinion may affect drug absorption
  • Active infection other than HBV or HCV
  • Other malignancy within the past 3 years or concurrent malignancy
  • Any other condition that in the investigator's opinion makes the patient unsuitable for the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: BMS-TACE

All participants receive chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE). Retreatment is performed on demand according to imaging every 6 weeks until progression, unacceptable toxicity, technical infeasibility, or withdrawal. Participants who were receiving anti-angiogenic therapy plus a PD-1/PD-L1 inhibitor concurrently with FOLFOX-HAIC continue the same regimen unchanged; participants who received FOLFOX-HAIC without systemic therapy do not start systemic therapy during the study. Other locoregional treatments (ablation, seed implantation) are not permitted unless the tumor is downstaged to allow curative treatment.

Visceral angiography of the celiac trunk, superior mesenteric artery and phrenic arteries maps the arterial supply of the tumor. A 2.8F microcatheter is placed super-selectively into each tumor-feeding artery by coaxial technique. A minimal-dose chemoemulsion (low-dose pirarubicin in a small volume of lipiodol) is injected first. Blank microspheres of any manufacturer are then delivered in ascending size order: 40-120 microns mixed with 5 mL contrast to occlude the distal tumor arterial bed; 100-300 microns for tumor arterial branches, with supplementary lipiodol emulsion if vascular lakes are seen; then 300-500 or 500-700 microns for the main feeding trunk. The endpoint is contrast stasis over 3-5 cardiac cycles with loss of at least 90% of intrahepatic tumor staining on completion angiography. Imaging is repeated every 6 weeks; retreatment follows protocol-defined criteria. Performed by one of two designated interventional radiologists.

다른 이름들:
  • bTACE
  • Blank microsphere embolization with low-dose chemotherapy

Low-dose pirarubicin emulsified with a small volume of lipiodol and injected intra-arterially into the tumor-feeding artery immediately before blank microsphere embolization, as the minimal-dose chemotherapy adjunct of each BMS-TACE session.

다른 이름들:
  • THP
  • Tetrahydropyranyl-adriamycin

Calibrated blank (non-drug-loaded) microspheres, 40-120, 100-300, 300-500 and 500-700 microns, of any manufacturer, delivered in ascending size order as the principal embolic agent in BMS-TACE.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) as Assessed by Investigator
기간: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

ORR is defined as the proportion of participants whose best overall response from enrollment (first BMS-TACE) is complete response (CR) or partial response (PR) per mRECIST, as assessed by the investigator together with a senior radiologist. Tumor assessment by contrast-enhanced CT or MRI is performed after the first BMS-TACE and every 6 weeks (±7 days) thereafter, regardless of treatment delays, until progression, unacceptable toxicity, death, withdrawal of consent, loss to follow-up or study termination. Analysis population: full analysis set (all enrolled participants); participants without post-baseline assessment are counted as non-responders.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival (PFS) Per mRECIST as Assessed by Investigator
기간: From enrollment until progression or death (up to approximately 30 months)

PFS is defined as the time from enrollment (first BMS-TACE) to the first documented radiological progression per mRECIST or death from any cause, whichever occurs first. Participants alive without progression are censored at the date of last tumor assessment. Estimated by the Kaplan-Meier method.

From enrollment until progression or death (up to approximately 30 months)
Disease Control Rate (DCR) Per mRECIST as Assessed by Investigator
기간: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

Proportion of participants whose best overall response is CR, PR or stable disease (SD) per mRECIST, using the same assessment schedule as the primary outcome.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
Duration of Response (DOR) Per mRECIST as Assessed by Investigator
기간: From first documented response until progression or death (up to approximately 30 months)

Among responders, the time from first documented CR or PR to first documented progression per mRECIST or death from any cause, whichever occurs first; responders without progression or death are censored at the last tumor assessment.

From first documented response until progression or death (up to approximately 30 months)
Overall Survival (OS)
기간: From enrollment until death from any cause (up to approximately 30 months)

OS is defined as the time from enrollment to death from any cause. Participants alive at last contact are censored at the date of last follow-up. Survival follow-up every 12 weeks (±7 days) after progression or start of new anticancer therapy, continuing until at least 12 months after the last participant's first BMS-TACE.

From enrollment until death from any cause (up to approximately 30 months)
Time to Untreatable Progression (TTUP)
기간: From enrollment until untreatable progression (up to approximately 30 months)

Time from enrollment to progression that precludes further BMS-TACE, including untreatable tumor progression and deterioration of liver function to Child-Pugh class C, as judged by the investigator. Participants still eligible for BMS-TACE are censored at last assessment.

From enrollment until untreatable progression (up to approximately 30 months)
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by Investigator
기간: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

Sensitivity analysis of the primary endpoint: proportion of participants with best overall response of CR or PR per RECIST 1.1, using the same assessment schedule.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
Incidence and Severity of Adverse Events Per NCI CTCAE Version 5.0
기간: From first BMS-TACE until 30 days after last BMS-TACE (up to approximately 13 months)

Number and proportion of participants with treatment-emergent adverse events, serious adverse events and treatment-related adverse events, graded per NCI CTCAE v5.0, from first BMS-TACE until 30 days after the last BMS-TACE or start of new anticancer therapy, whichever is first. Safety set: all participants who receive at least one BMS-TACE.

From first BMS-TACE until 30 days after last BMS-TACE (up to approximately 13 months)

기타 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in Quality of Life Per EORTC QLQ-C30
기간: Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

Change from baseline in health-related quality of life assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Scores for the global health status/quality of life scale, the five functional scales, and the symptom scales/items are linearly transformed to range from 0 to 100. Higher global health status/quality of life and functional scores indicate better quality of life or functioning; higher symptom scores indicate worse symptoms/problems. Change from baseline is calculated separately for each scale/item as the post-baseline score minus the baseline score.

Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)
Change From Baseline in Quality of Life Per EORTC QLQ-HCC18
기간: Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

Change from baseline assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18). This 18-item module assesses fatigue, body image, jaundice, nutrition, pain, fever, abdominal swelling, and sexual interest. Each scale/item score is linearly transformed to range from 0 to 100; higher scores indicate worse symptoms/problems or poorer health-related quality of life. Change from baseline is calculated separately for each scale/item as the post-baseline score minus the baseline score.

Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Jinhua Huang, MD, PhD, Sun Yat-Sen University Cancer Center
  • 연구 책임자: Zhimei Huang, MD, Sun Yat-Sen University Cancer Center

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 10월 20일

기본 완료 (추정된)

2028년 10월 1일

연구 완료 (추정된)

2029년 3월 1일

연구 등록 날짜

최초 제출

2026년 10월 9일

QC 기준을 충족하는 최초 제출

2026년 11월 15일

처음 게시됨 (실제)

2026년 11월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 15일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • SL-B2025-858-02

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .